Hims & Hers Health (HIMS) EBITDA Margin (2020 - 2026)

Hims & Hers Health has disclosed EBITDA Margin across 7 years of filings, most recently posting 12.9% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 1781.0% year-over-year to 12.9%; the TTM figure through Jun 2026 stood at 5.99% (down 1223.0% YoY), while the FY2025 annual figure was 4.5%, up 31.0% from the prior year.
• EBITDA Margin came in at 12.9% for Q2 2026 at Hims & Hers Health, roughly flat from 12.88% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 9.88% in Q1 2025 to a low of 17.78% in Q2 2022.
• Average EBITDA Margin over 5 years is 3.36%, with a median of 1.97% recorded in 2023.
• Year-over-year, EBITDA Margin surged 7584 bps in 2022 and sank 2276 bps in 2026.
• Over 5 years, EBITDA Margin stood at 6.94% in 2022, then soared by 98 bps to 0.16% in 2023, then surged by 2483 bps to 3.86% in 2024, then tumbled by 62 bps to 1.49% in 2025, then tumbled by 968 bps to 12.9% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 12.9% in Q2 2026, 12.88% in Q1 2026, and 1.49% in Q4 2025.